Gaucher disease (GD) is a genetic disorder that causes fatty substances to accumulate to harmful levels in organs and tissues, often resulting in hepatosplenomegaly, anemia, thrombocytopenia, bone pain and fractures, and conditions like arthritis. GD is rare, and even specialists struggle to recognize and diagnose the condition. Delays to initiation of therapy are common and can result in irreversible complications.
During this 60-minute recorded symposium, expert panelists will discuss GD, including its less commonly reported manifestations, diagnostic pathways, and patient-centric multidisciplinary management of the disorder.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physician associates (PAs), nurse practitioners (NPs), primary care practitioners, nurses, pharmacists, genetic counselors, and pediatricians, specializing in hematology, neurology, hepatology, gastroenterology, pulmonologists, radiology, and orthopedic surgery
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Roshan Lal reports the following financial relationships:
Advisory Board: Takeda Pharmaceuticals U.S.A., Inc. (Gaucher Advisory Board)
Consultant: FDNA INC.
Speakers Bureau: BioMarin (PKU)
Dr. Heldermon reports the following financial relationships:
Advisory Board: Chiesi USA, Inc.; Orphazyme; REGENXBIO Inc.; and Sanofi
Consultant: Atheneum; Cardinal Health; Curio Science; Guidepoint Global; IntrinsiQ Specialty Solutions; Reckner Healthcare; Sage Research; Sanofi; Targeted Oncology; and Third Bridge Consulting
Stock Shareholder (ownership Interest): Lacerta Therapeutics
Dr. Weinreb reports the following financial relationships:
Advisory Board: AVROBIO, Inc. (Disease Monitoring Safety Board); Pfizer Inc. (Medical Advisory Board for the Taliglucerase alfa Gaucher Registry); Sanofi (Scientific Advisory Board for the International Collaborative Gaucher Group (ICGG) Gaucher Registry); and Takeda Pharmaceuticals U.S.A., Inc. (Medical Advisory Board for Gaucher Disease)
Consultant: Pfizer Inc. and Sanofi
Speakers Bureau: Sanofi
Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).